Nine months of rheumatoid arthritis suppression with one stem cell dose?
Rheumatoid arthritis patients given a single intravenous dose of Mesoblast's novel stem cell therapy were still demonstrating therapeutic benefits nine months later, according to new Phase 2 data from the Melbourne, Australia-based company.